Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs.

One of the most critical issues to be solved in regard to cancer chemotherapy is the need to establish a method for predicting efficacy or toxicity of anticancer drugs for individual patients. To identify genes that might be associated with chemosensitivity, we used a cDNA microarray representing 23,040 genes to analyze expression profiles in a panel of 85 cancer xenografts derived from nine human organs. The xenografts, implanted into nude mice, were examined for sensitivity to nine anticancer drugs (5-fluorouracil, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride, adriamycin, cyclophosphamide, cisplatin, mitomycin C, methotrexate, vincristine, and vinblastine). Comparison of the gene expression profiles of the tumors with sensitivities to each drug identified 1,578 genes whose expression levels correlated significantly with chemosensitivity; 333 of those genes showed significant correlation with two or more drugs, and 32 correlated with six or seven drugs. These data should contribute useful information for identifying predictive markers for drug sensitivity that may eventually provide "personalized chemotherapy" for individual patients, as well as for development of novel drugs to overcome acquired resistance of tumor cells to chemical agents.

[1]  V. Kickhoefer,et al.  The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines. , 2000, Cancer research.

[2]  B. Leyland-Jones,et al.  Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. , 1991, Cancer research.

[3]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[4]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[6]  S. Takao,et al.  Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. , 1999, Journal of the National Cancer Institute.

[7]  R. Lotan,et al.  Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. , 1991, Carbohydrate research.

[8]  R. Hoffman,et al.  Clinical applications of the histoculture drug response assay. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  M. Flens,et al.  Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues. , 1998, The American journal of pathology.

[10]  T. Nomura,et al.  Responsiveness of subcutaneous human glioma xenografts to various antitumor agents. , 1990, Anticancer research.

[11]  N. Ordóñez,et al.  Ultrastructural and morphometric features of poorly differentiated and undifferentiated lung tumors. , 1989, Ultrastructural pathology.

[12]  T Tanaka,et al.  Identification by cDNA microarray of genes involved in ovarian carcinogenesis. , 2000, Cancer research.

[13]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[14]  T Tanaka,et al.  Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. , 2001, Cancer research.

[15]  M. Shimizu,et al.  Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-Hydroxystaurosporine). , 1999, Cancer research.

[16]  J. Styles,et al.  Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance , 2001, Oncogene.

[17]  J. Fogh,et al.  Considerations in the use of nude mice for cancer research , 2004, Cancer and Metastasis Reviews.

[18]  E. Schuetz,et al.  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.

[19]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[20]  R. Goorha,et al.  The mouse mitotic checkpoint gene bub1b, a novel bub1 family member, is expressed in a cell cycle-dependent manner. , 1999, Genomics.

[21]  V. Kickhoefer,et al.  The M r 193 , 000 Vault Protein Is Up-Regulated in Multidrug-resistant Cancer Cell Lines 1 , 2000 .

[22]  E. Tahara.  Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis , 1995, Cancer.

[23]  A. Rao,et al.  The cause of G2-arrest in Chinese hamster ovary cells treated with anticancer drugs. , 1976, Journal of the National Cancer Institute.

[24]  M. Korc,et al.  Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. , 1999, Cancer research.

[25]  I. Pastan,et al.  The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. , 1987, The Journal of biological chemistry.

[26]  A. Ryo,et al.  Identification and characterization of genes associated with human hepatocellular carcinogenesis. , 1999, Cancer research.

[27]  T. Nomura,et al.  Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses , 2004, Cancer Chemotherapy and Pharmacology.

[28]  T. Nomura,et al.  Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose , 1989, Cancer.

[29]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[30]  D. Waxman,et al.  Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. , 1995, Biochemical pharmacology.

[31]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[32]  T. Nomura,et al.  Responsiveness of Human Gastric Tumors Implanted in Nude Mice to Clinically Equivalent Doses of Various Antitumor Agents , 1988, Japanese journal of cancer research : Gann.

[33]  Y. Seo,et al.  Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations. , 2000, Anticancer research.

[34]  B. Barlogie,et al.  Cell cycle stage-dependent induction of G2 phase arrest by different antitumor agents. , 1978, European journal of cancer.

[35]  K. Keyomarsi,et al.  Expression of cytochromes P450 in human breast tissue and tumors. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[36]  A Gouyette,et al.  Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  M. Ratain,et al.  Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[38]  A. Krishan,et al.  Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells. , 1993, Biochemical pharmacology.